While open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of promoting spin-offs, start-ups, and biotech SMEs, the open science movement aims to establish a completely new model for how to spur innovation. Eliminating intellectual property-related restrictions, open biology promises rapid and local production of biomaterials, diagnostics, or genome-edited crops in countries with no established IP system.
Merck and 4SC collaborate in immunooncology
Latest News4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Merck’s checkpoint blocker avelumab plus 4SC’s HDAC I blocker domatinostat.
The biotech boost – when, if not now?
BackgroundDespite the threat of a looming climate catastrophe, low oil prices and giant industrial conglomerates addicted to fossil resources continue to stifle industrial biotechnology products and innovation. The European Biotechnology Network is now providing a foot up for companies that want to help themselves by launching three very different projects aimed at pushing the bioeconomy forward.
Novo Holdings invest US$12m in AMR companies
Latest NewsMutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund.
Fighting sepsis mortality
Latest NewsCritical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality.
Zelluna: Scientist turns CEO
AppointmentsNorwegian biopharma company Zelluna Immunotherapy appointed erstwhile CSO Namir Hassan as Chief Executive Officer.
Antabio SAS advances cystic fibrosis programme
Latest NewsAntabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients
Creoptix: New woman at the helm
AppointmentsCreoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, has named Line Stigen Raquet as Chief Executive Officer.
Hydrogel fights wound infection and inflammation
Latest NewsSwedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds.
Is your reality quite different from other people’s reality?
OpinionWhile open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of promoting spin-offs, start-ups, and biotech SMEs, the open science movement aims to establish a completely new model for how to spur innovation. Eliminating intellectual property-related restrictions, open biology promises rapid and local production of biomaterials, diagnostics, or genome-edited crops in countries with no established IP system.
Is your reality quite different from other people’s reality?
OpinionWhile open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of promoting spin-offs, start-ups, and biotech SMEs, the open science movement aims to establish a completely new model for how to spur innovation. Eliminating intellectual property-related restrictions, open biology promises rapid and local production of biomaterials, diagnostics, or genome-edited crops in countries with no established IP system.